Zydus Lifesciences gets NoC for ZDS-Varenicline Tablets 0.5 &1 mg
This is the group’s first NOC approval in Canada
Zydus Lifesciences has received Notice of Compliance (NoC) from Health Canada for ZDS-Varenicline tablets 0.5 &1 mg. This is the group’s first NOC approval in Canada.
Varenicline is used as an aid in smoking cessation. It is a partial nicotinic acetylcholine receptor agonist, designed to partially activate this system while displacing nicotine at its sites of action in the brain. ZDS-Varenicline tablets will be produced at Zydus Lifescience, SEZ, Ahmedabad. Varenicline tablets had annual sales of 15 million Canadian dollar in Canada (IQVIA MAT December 2024).
Zydus Lifesciences (formerly known as Cadila Healthcare), a company limited by shares, incorporated and domiciled in India, operates as an integrated pharmaceutical company with business encompassing the entire value chain in the research, development, production, marketing and distribution of pharmaceutical products.
